Inhibrx Biosciences, Inc.
INBX · XNASCIK 2007919fmd_0KBXPCEX6JXXF093S50V88VPXDManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2023 to Jun 30, 2026, 14 periods
| Line item | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Total revenues | 2 | 0 | 1 |
| Research and development | 192 | 204 | 113 |
| Total operating expenses | 221 | 332 | 136 |
| Operating income | (219) | (331) | (135) |
| Interest expense | 32 | 13 | 12 |
| Other non-operating income (expense) | (21) | 2,019 | (5) |
| Income before taxes | (240) | 1,688 | (140) |
| Income tax expense | 0 | 0 | 0 |
| Net income from continuing operations | (240) | 1,688 | (140) |
| Net income | (241) | 1,688 | (140) |